Navigation Links
150-year-old Drug May Provide 'Off' Time Relief for People with Advanced Parkinson's Disease
Date:4/19/2017

BOSTON, April 19, 2017 /PRNewswire-USNewswire/ -- New research provides evidence that an old drug may provide relief for people with advanced Parkinson's, according to a study released today that will be presented at the American Academy of Neurology's 69th Annual Meeting in Boston, April 22 to 28, 2017.

When it comes to the treatment of Parkinson's disease, the oral drug levodopa has long been considered the gold standard, improving quality of life and longevity. But as the disease progresses, the effects of the medication can partially wear off more quickly after each dose, leaving people to experience "off" time, which are periods of immobility related to temporary unresponsiveness to medication. Parkinson's symptoms, such as slowness and muscle rigidity, often make movement difficult.

"If a person with Parkinson's disease can reduce their 'off' times, that can have a great impact on their everyday life," said study author Regina Katzenschlager, MD, of Danube Hospital, affiliated with the Medical University of Vienna, Austria. "In some patients in the trial, the insecurity of unpredictable periods of incapacity was completely alleviated."

The drug apomorphine, first produced in 1865, was first used to treat advanced Parkinson's disease in the United States in 1950. Its use grew in the 1990s when European doctors starting using subcutaneous infusions of the drug to treat fluctuations in mobility that could not be controlled by the pills. Despite its use in many countries of the world, high-level evidence from randomized, blinded studies of its effectiveness and safety has up until now been lacking.

In this phase III study, researchers recruited 107 people with advanced Parkinson's disease from 23 centers in seven countries. Participants were randomly selected to receive either apomorphine subcutaneous infusion or a placebo saline infusion. The infusion was administered over a period of 14 to 18 hours each day via a small portable pump similar to the sort used in the treatment of type 1 diabetes.

The study found that those who were given apomorphine had a significantly greater reduction of "off" time than those who were given the placebo infusion, with, on average, 2.5 hours less "off" time per day, while those who received the placebo infusion had an average 30 minutes per day reduction in "off" time. This improvement was apparent within the first week of treatment. At the same time, for those who received apomorphine, there was an increase of "on" time without the abnormal involuntary movements known as dyskinesias that are often observed with levodopa.

Participants were also asked to evaluate how well they thought the treatment worked. Those who received apomorphine gave their treatment higher scores at week 12 than those who received the placebo infusion. In the apomorphine group, 71 percent of patients felt improved, compared to 18 percent on placebo, whereas 19 percent worsened on apomorphine compared to 45 percent on placebo. Apomorphine was generally well tolerated and there were no serious side effects.

"It is our hope that these findings confirming the efficacy of apomorphine infusion will encourage doctors in the United States to offer this treatment to their patients and assess its efficacy in their own clinical practice," said Katzenschlager.

The study was supported by Britannia Pharmaceuticals Ltd., the maker of apomorphine.

Learn more about Parkinson's disease at www.aan.com/patients.

The American Academy of Neurology is the world's largest association of neurologists and neuroscience professionals, with 32,000 members. The AAN is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer's disease, stroke, migraine, multiple sclerosis, concussion, Parkinson's disease and epilepsy.

For more information about the American Academy of Neurology, visit http://www.aan.com or find us on Facebook, Twitter, Google+, LinkedIn and YouTube.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/150-year-old-drug-may-provide-off-time-relief-for-people-with-advanced-parkinsons-disease-300442207.html


'/>"/>
SOURCE American Academy of Neurology
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Global Information Online Market Research Portal Provides Complimentary Sample Service for Customers to Preview Reports by Global Industry Analysts
2. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
3. Novelos Therapeutics Provides Product Pipeline Update
4. Sony Biotechnology Inc.s New Technology for Science Provides Researchers Results in Color
5. Survey of Participants from Landmark GRACE Trial Provides Patients Perspectives from an HIV Clinical Study
6. Oncologix (OCLG) Plans Expansion; Talks Underway with Two Healthcare Service Providers
7. Ampio Pharmaceuticals Provides Clinical Updates
8. More Than 100 Winning Medicare Bidders In Maryland Dont Have Proper Licenses To Provide Medical Equipment To Patients
9. Life Care Medical Devices Provides Mid-Year 2013 Corporate Review and Outlines Near-Term Corporate Milestones
10. Neiman Center Issues Policy Brief Outlining Innovative Health Care Payment Models to Provide Cost-Effective Specialty Care for Patients
11. PDL BioPharma Provides Second Quarter 2013 Royalty Revenue Guidance of $143 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/11/2018)... ... August 10, 2018 , ... US Capital Global ... a $2 million seed funding round. Carepoynt is an emerging leader in the digital ... of a more rewarding and engaging healthcare ecosystem. , Headquartered in San Francisco, US ...
(Date:8/9/2018)... SAN LEANDRO, Calif (PRWEB) , ... August 09, 2018 , ... ... communicate and socialize with others. Given how widespread autism is, (approximately 1 in 68 ... autism cannot be “cured,” there are options to help teach a child with autism ...
(Date:8/7/2018)... ... 07, 2018 , ... Commissioner Gottlieb’s FDA:, Analysis of First Year and a ... ET, http://www.fdanews.com/commissionergottliebsfda , Under Commissioner Scott Gottlieb, changes at the FDA ... may have gotten hurt. , And Gottlieb is just getting started. , Mark the ...
Breaking Medicine Technology:
(Date:8/14/2018)... ... August 14, 2018 , ... ... Recreational Group, a leading provider of residential and commercial recreational surfacing products across ... surfacing industry, with products used across a wide range of markets and customers. ...
(Date:8/11/2018)... ... August 10, 2018 , ... Georgia Urology, the largest urology ... Drs. Brent Sharpe and Froylan Gonzalez recently widened that scope by debuting two ... June 27, the physicians combined their expertise to perform a nephrectomy and an ...
(Date:8/9/2018)... ... August 09, 2018 , ... ... outcomes by simplifying medication adherence monitoring with Smart-pill bottle and mobile applications, ... in the App Orchard. , The DoseSmart medication management and medication adherence ...
(Date:8/7/2018)... ... 2018 , ... Today Springfield Creamery added six new Organic ... yogurts are made with milk from grass-fed cows who enjoy a diet of ... Nancy’s sources the milk from organic family-owned farms, all within 60 miles of ...
(Date:8/3/2018)... ... August 03, 2018 , ... ... smartglasses, is pleased to announce the launch of its online store. The Lucyd ... designer frames, and other innovations in spectacles. , The eShop will have ...
Breaking Medicine News(10 mins):